(Press-News.org) The development of innovative medicines is an expensive, time-consuming and risky business. On average, it usually takes at least a decade and billions of dollars to bring a new drug from project initiation to approval. Identifying effective targets and conducting biological analysis is the first step in the process and remains a top priority in drug development.
To facilitate for maximum data privacy and data security, Insilico Medicine ("Insilico"), developed a hardware platform, PandaOmics Box, that does not require Internet access and allows for on-premise biological analytics, target identification, biomarker discovery, indication prioritization and advanced research in personalized medicine and drug discovery.
The PandaOmics Box is a seamless integration of Insilico's proprietary generative biology AI software PandaOmics, extensive scientific database, and advanced hardware system with state-of-the-art computational power and chip-level confidential computing. Designed for on-premise deployment, the PandaOmics Box allows the product to operate efficiently in a completely offline mode, therefore provides a secure environment for privacy data analysis.
The solution is centered on PandaOmics, which encompasses more than 20 predictive models and generative biology models, and includes a full spectrum of transcriptomics, genomics, epigenomics, proteomics, single cell data and compound information generated by the scientific community. It supports professional target ranking, analysis and filters, empowering more efficient and convenient research for potential targets and biomarkers.
It is further enhanced by a powerful local Large Language Model (LLM), marking it as a truly all-encompassing tool for research. Its array of additional superior features include: ChatPandaGPT, which allows researchers to engage with Insilico Medicine's knowledge graph database via intuitive, natural language conversations; Gene-Disease Report function, which streamlines the user's research efforts by automatically generating comprehensive reports that provide a comprehensive analysis of a specific research area, and Paper Drafting Tool, which is designed to assist researchers in creating well-structured draft papers, making the transition from research to publication smoother.
Additionally, the system is equipped with OpenAPI framework, and allows Bioinformatics access to PandaOmics' extensive database and advanced AI algorithms. This feature provides researchers the flexibility to develop their own custom analyses, enabling them to create innovative methods that blend with their proprietary data for deeper insights.
“Personal medical and biological data must be secure and there is nothing more secure than a device that does not connect to the Internet, does not even have WiFi and even internally uses on-chip confidential computing but can perform many research functions that previously required access to the Internet or were not possible at all. While many hospitals, institutes, and biotech companies hold large amounts of data of their own, they are concerned that putting data in the cloud will lose its value or violate data privacy regulations. We want to help them unlock the value of that data, generate unprecedented value for the patients, and perform cutting-edge research.” said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “We offer on-premise PandaOmics Box that supports scientists to conduct cutting-edge tasks such as target identification, biomarker discovery, and indication prioritization in one hardware with no internet connection. Also, the array of exceptional features supported by LLM and open API further enhance the research experience.”
Overall, PandaOmics Box, the innovative platform, is tailor-made to transform the research landscape, empowering researchers to excel in target identification, biomarker discovery and indication prioritization. Leveraging Insilico Medicine's exceptional AI capabilities, researchers are equipped with a powerful ally in their quest for groundbreaking advancements in target identification and drug development.
Insilico Medicine is a pioneer in using generative AI for drug discovery and development. The Company first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.AI platform, which includes generative biology, chemistry, and medicine.
Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 promising therapeutic assets and has advanced seven molecules to the clinical stage. In March 2024, the Company published a paper in Nature Biotechnology that discloses the raw experimental data and the preclinical and clinical evaluation of its lead drug – a potentially first-in-class TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis discovered and designed using generative AI currently in Phase II trials with patients.
About Insilico Medicine
Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
END
Insilico releases AI-powered hardware platform, PandaOmics Box for on-premise drug discovery and personalized medicine research
2024-07-25
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
RSNA makes strides in narrowing radiology gender gap
2024-07-25
OAK BROOK, Ill. – The radiology gender gap is decreasing, but there remains work to be done, according to an editorial published today in RadioGraphics, a journal of the Radiological Society of North America (RSNA).
In 2022, nearly half of residents and fellows in Accreditation Council for Graduate Medical Education
(ACGME)–accredited programs were female. However, less than 27% of active diagnostic radiologists and only 10% of active interventional radiologists are female. Within the 48 largest medical specialty groups, diagnostic radiology ranks 41st and ...
Vital support for early career researchers in aging boosted with Hearst Foundations gift to American Federation for Aging Research (AFAR)
2024-07-25
NEW YORK, NY– The American Federation for Aging Research (AFAR) is pleased to announce a $450,000 grant from The Hearst Foundations in support of the Grants for Junior Faculty program.
The Grants for Junior Faculty provide early career investigators with up to $150,000 for one to two years to support research focused on aging processes and age-related diseases. The $450,000 grant from Hearst Foundations will fully underwrite three Grants for Junior Faculty over the next three years.
Selected ...
Nonreciprocal interactions go nonlinear
2024-07-25
Using two optically trapped glass nanoparticles, researchers observed a novel collective Non-Hermitian and nonlinear dynamic driven by nonreciprocal interactions. This contribution expands traditional optical levitation with tweezer arrays by incorporating the so called non-conservative interactions. Their findings, supported by an analytical model developed by collaborators from Ulm University and the University of Duisburg-Essen, were recently published in Nature Physics.
Fundamental forces like gravity and electromagnetism are reciprocal, meaning two ...
Svalbard: Non-native species are threatening vulnerable plant life
2024-07-25
New, non-native plant species are constantly being discovered in Svalbard, and researchers are working to ascertain what threat these species pose to the native plants.
So far, the Arctic has managed to avoid one of the most serious threats to biodiversity on Earth. This is also true for Svalbard, but things could change very quickly, and researchers want to find out how to counteract this threat.
“Increased human activity heightens the risk of new plant species being introduced. And climate change increases the risk of invasive species establishing themselves,” says Kristine Bakke Westergaard.
She is an associate ...
Cultivating better leadership: KLU and partners create Texl.org - a free, scientific evidence-based 360-degree assessment tool
2024-07-25
Available to anyone, anywhere, at anytime, Texl.org allows individuals and organizations to create scientifically valid surveys in less than five minutes. In drag-and-drop fashion, survey creators can choose from an ever-growing list of 50 validated scales, measuring aspects ranging from team conflict to personal initiative and transformational leadership.
“The point of science is to develop knowledge that ultimately is to the benefit of society. Unfortunately, we are not always great in translating our knowledge so that it is usable for practitioners out there. With Texl we’re changing that,” explains Professor Niels Van Quaquebeke, ...
FAU researcher receives grant to personalize radiation therapy for cancer
2024-07-25
While chemotherapy has advanced in personalization, personalized radiation therapy for cancer remains underdeveloped. Current cancer treatment methods – including radiation therapy – are intricate, lack personalization, and rely heavily on the expertise of medical teams. Medical image analysis and machine learning hold great promise for enhancing personalized oncology. However, challenges persist such as limited high-quality data and data complexity.
Wazir Muhammad, Ph.D., principal investigator and ...
MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab
2024-07-25
HOUSTON and MIAMI ― The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.
Leveraging MD Anderson’s clinical infrastructure and research expertise together with Summit’s innovative, investigational, potential first-in-class PD-1/VEGF bispecific antibody, the collaboration is designed to quickly discover additional opportunities for ivonescimab, including several tumors outside of its current development plan. MD Anderson will lead multiple clinical trials in several tumor types to evaluate the safety and potential clinical ...
Warming has more impact than cooling on Greenland's "firn"
2024-07-25
Scientists have known from ice core research that it's easier to melt an ice sheet than to freeze it up again. Now, they know at least part of the reason why, and it has to do with ice's "sponginess," according to a new study published July 24 in The Cryosphere.
The study uses a physics-based numerical model to assess the impacts of warming and cooling on firn, the porous layer between snow and glacial ice, over the entire Greenland Ice Sheet. Megan Thompson-Munson, a CIRES and ATOC PhD student, led the study alongside ...
The Texas Heart Institute implants BiVACOR® Total Artificial Heart
2024-07-25
Houston, Texas, July 25, 2024 – The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR’s TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces both ventricles of a failing heart.
The first-in-human clinical ...
University of Washington researchers take flight with new insights on bat evolution
2024-07-25
University of Washington Researchers Take Flight with New Insights on Bat Evolution
Video Interview with Authors - https://youtu.be/6rogrh2_HN0
In new research published in PeerJ Life & Environment, researchers from the University of Washington, University of Texas at Austin and Oregon Institute of Technology, led by undergraduate student Abby Burtner, have advanced our understanding of the evolutionary origins of flight in bats. The study, titled "Gliding toward an Understanding of the Origin of Flight in Bats," employs phylogenetic comparative methods to explore the evolutionary transition from gliding to powered flight in these unique mammals.
Bats ...